Chief Business & Strat Officer
Mon, Aug 12, 2024
Aug 12
exercised or converted securities in APLS
5,201 shares @ $0.00
Decreased holdings by -26.00%
Net across this filing: +9.40% (+5,201 shares)
Win rate excludes trades classified as routine (tax, 10b5-1, exercise, gift).
APLSApellis Pharmaceuticals, Inc.
HealthcareBiotechnology